Determination of Cathepsin B Expression May Offer Additional Prognostic Information for Ovarian Cancer Patients

Human epididymis protein 4 (HE4) is an ovarian cancer marker. Various cut-off values of the marker in blood are recommended, depending on the method used for its determination. An alternative biosensor for HE4 determination in blood plasma has been developed. It consists of rabbit polyclonal antibody against HE4, covalently attached to a gold chip via cysteamine linker. The biosensor is used with the non-fluidic array SPRi technique. The linear range of the analytical signal response was found to be 2–120 pM, and the biosensor can be used for the determination of the HE4 marker in the plasma of both healthy subjects and ovarian cancer patients after suitable dilution with a PBS buffer. Precision (6–10%) and recovery (101.8–103.5%) were found to be acceptable, and the LOD was equal to 2 pM. The biosensor was validated by the parallel determination of a series of plasma samples from ovarian cancer patients using the Elecsys HE4 test and the developed biosensor, with a good agreement of the results (a Pearson coefficient of 0.989). An example of the diagnostic application of the developed biosensor is given—the influence of ovarian tumor resection on the level of HE4 in blood serum.

Download Full-text

Determination of Both TP53 Mutation Status and the Amount of p53 Protein Has Limited Diagnostic Importance for Patients with Ovarian Cancer

Current Medicinal Chemistry ◽

10.2174/0929867329666220112141211 ◽

2022 ◽

Vol 29 ◽

Author(s):

Sebastian M. Klein ◽

Maria Bozko ◽

Astrid Toennießen ◽

Nisar P. Malek ◽

Przemyslaw Bozko

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Tp53 Mutation ◽

P53 Protein ◽

Mutation Status ◽

Tumor Tissues ◽

Tp53 Status ◽

Diagnostic Importance

Background: Ovarian cancer is one of the most aggressive types of gynecologic cancers. Many patients have a relapse within two years after diagnosis and subsequent therapy. Among different genetic changes generally believed to be important for the development of cancer, TP53 is the most common mutation in the case of ovarian tumors. Objective: Our work aims to compare the outcomes of different comparisons based on the overall survival of ovarian cancer patients, determination of TP53 status, and amount of p53 protein in tumor tissues. Methods: We analyzed and compared a collective of 436 ovarian patient’s data. Extracted data include TP53 mutation status, p53 protein level, and information on the overall survival. Values for p53 protein level in dependence of TP53 mutation status were compared using the Independent-Samples t-Test. Survival analyses were displayed by Kaplan-Meier plots, using the log-rank test to check for statistical significance. Results: We have not found any statistically significant correlations between determination of TP53 status, amount of p53 protein in tumor tissues, and overall survival of ovarian cancer patients. Conclusion: In ovarian tumors both determination of TP53 status as well as p53 protein amount has only limited diagnostic importance.

Download Full-text

Immunocytochemical Determination of EGFR, OV 632 and OC 125 in Primary Ovarian Cancer Patients

Oncology ◽

10.1159/000227446 ◽

1995 ◽

Vol 52 (2) ◽

pp. 145-149 ◽

Cited By ~ 1

Author(s):

P. Athanassiadou ◽

P. Athanassiades ◽

K. Kyrkou ◽

D. Lazaris ◽

G. Kyragiannis ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Primary Ovarian Cancer

Download Full-text

Molecular determination of the clonal relationships between multiple tumours in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant

10.26226/morressier.578f37fed462b8028d88fec0 ◽

2016 ◽

Author(s):

Ina Geurts-Giele

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Molecular Determination

Download Full-text

Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer

International Journal of Gynecological Cancer ◽

10.1136/ijgc-2019-000492 ◽

2019 ◽

Vol 29 (6) ◽

pp. 1057-1063

Author(s):

Naoko Komura ◽

Seiji Mabuchi ◽

Eriko Yokoi ◽

Kotaro Shimura ◽

Mahiru Kawano ◽

...

Keyword(s):

Ovarian Cancer ◽

Platelet Count ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Prognostic Nutritional Index ◽

Disease Specific Survival ◽

Prognostic Information ◽

Nutritional Index ◽

Pre Treatment ◽

Disease Specific

ObjectiveBoth pre-treatment prognostic nutritional index and platelet count were reported to be independent prognostic factors in epithelial ovarian cancer patients. However, their relationship has not been investigated. The aim of this study was to investigate the association between the pre-treatment prognostic nutritional index and platelet count, and to compare their utility as prognostic indicators for patients with epithelial ovarian cancer.MethodsClinical data from epithelial ovarian cancer patients treated between April 2007 and March 2016 were collected and retrospectively reviewed. The association between the pre-treatment prognostic nutritional index and platelet count was evaluated using Spearman’s rank correlation coefficient. After determining the cut-off values for the pre-treatment platelet count and prognostic nutritional index for predicting disease-specific survival by time-dependent receiver operating characteristic (ROC) curve analysis, we compared the clinical utility of platelet counts and the prognostic nutritional index.ResultsA total of 308 patients were included in the analysis. Median age was 57 (range 16–81) years. The International Federation of Gynecology and Obstetrics (FIGO) clinical stage at initial diagnosis was stage I in 137 patients (44.5%), stage II in 27 patients (8.8%), stage III in 96 patients (31.2%), and stage IV in 48 patients (15.6%). Most patients (37.7%) had serous adenocarcinoma. Of the 295 patients who underwent primary or interval debulking surgery, optimal debulking was performed in 240 patients (77.9%). Decresed pre-treatment prognostic nutritional index was correlated with increased pre-treatment platelet count (p<0.0001), and when compared, the prognostic nutritional index had a significantly greater area under the ROC curve value than the platelet count for predicting disease-specific survival (0.8348 vs 0.6413, p=0.0007). An elevated platelet count was significantly associated with a shorter disease-specific survival in epithelial ovarian cancer patients (p<0.0001). However, when the prognostic nutritional index was adjusted, an elevated platelet count did not provide any prognostic information (lower prognostic nutritional index, p=0.45; higher prognostic nutritional index, p=0.77).ConclusionsThe pre-treatment prognostic nutritional index was superior to the platelet count for predicting disease-specific survival for epithelial ovarian cancer patients. Although pre-treatment thrombocytosis was reported to be an independent poor prognostic factor in epithelial ovarian cancer patients, it generally reflects a lower prognostic nutritional index, and did not provide any prognostic information when the prognostic nutritional index was adjusted.

Download Full-text